|
Language for communicating frequentist results about treatment effects
|
|
187
|
46841
|
October 10, 2021
|
|
First RCT of Lopinavir–Ritonavir on SARS-CoV2
|
|
38
|
9485
|
October 8, 2021
|
|
Interpretation of the REGEN-COV trial
|
|
20
|
345
|
October 7, 2021
|
|
Extensions of 'worst-rank' score methods with outcomes truncated by death
|
|
13
|
558
|
September 2, 2021
|
|
Resources for Mixed-Effect Models in Medical Contexts
|
|
7
|
645
|
August 8, 2021
|
|
Heterogeneity in RCTs with continuous outcome
|
|
19
|
1796
|
July 2, 2021
|
|
Default Using R package to implement Bayesian phase I/II dose-finding design for three outcomes
|
|
10
|
847
|
June 10, 2021
|
|
Summary Statistics vs Raw Data
|
|
7
|
2313
|
February 28, 2021
|
|
Analysis of 2x2 trial with anticipated treatment interaction
|
|
8
|
1260
|
February 24, 2021
|
|
Multiplicity in clinical trials with hierarchical strategy
|
|
2
|
911
|
December 30, 2020
|
|
What is a fake measurement tool and how are they used in RCT
|
|
44
|
3992
|
December 20, 2020
|
|
Quality of remdesivir trials
|
|
41
|
5079
|
November 18, 2020
|
|
RCT trials for COVID study vaccines
|
|
0
|
971
|
October 24, 2020
|
|
Can treatment B be superior after the RCT if it was thought that treatment A is superior before the RCT?
|
|
5
|
1185
|
October 13, 2020
|
|
"Open label, double-masked trial"
|
|
0
|
1125
|
October 13, 2020
|
|
ANCOVA with randomized and nonrandomized groups
|
|
4
|
1132
|
September 30, 2020
|
|
Time since randomization and causality
|
|
2
|
1008
|
September 27, 2020
|
|
Bayesian Solutions for Challenges to Frequentist Statistics
|
|
0
|
2480
|
September 22, 2020
|
|
Empirical Bayes for RCT Interpretarion
|
|
8
|
2935
|
August 11, 2020
|
|
Re-starting a Bayesian group sequential design trial after stopping it
|
|
4
|
1191
|
August 11, 2020
|
|
MERINO trial - adjusting for infection source
|
|
3
|
1475
|
August 3, 2020
|
|
Thoughts on 'representativeness' and 'generalizability'
|
|
6
|
1815
|
July 19, 2020
|
|
Interpretation of INTERACT-2 Study in Intracerebral Hemorrhage
|
|
3
|
1538
|
June 15, 2020
|
|
Open-label RCT of triple combination (LPV/r, Ribavirin, Interferon) on SARS-CoV2
|
|
1
|
1606
|
May 15, 2020
|
|
Type I error in a specific design of 2-parallel group study
|
|
3
|
1897
|
March 11, 2020
|
|
RCT generalizability and interactions with treatment
|
|
8
|
2348
|
March 10, 2020
|
|
Presenting models of multiple (potentially recurring) outcomes
|
|
1
|
1529
|
March 6, 2020
|
|
Power for interaction effects
|
|
6
|
1643
|
February 24, 2020
|
|
Open label RCT: Placebo or Real effect?
|
|
5
|
2022
|
February 5, 2020
|
|
Handling withdrawn study subjects
|
|
6
|
1665
|
February 4, 2020
|
